Drugs / flu matrix peptide p58-66
last change Oct 2006 re-read 2 minutes ago

flu matrix peptide p58-66

Peptide

Developed for
cutaneous melanoma
Investigated by
Baylor Health Care System · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00003792 Apr 1999 → Oct 2006 cutaneous melanoma Baylor Health Care System Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as flu matrix peptide p58-66 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003792
Modality Peptide “flu matrix peptide p58-66” NCT00003792